Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
38.56 USD +0.68% Intraday chart for Neurogene Inc. +0.26% +98.97%
Jul. 01 Neurogene Inc.(NasdaqGM:NGNE) added to Russell Small Cap Comp Value Index CI
Jul. 01 Neurogene Inc.(NasdaqGM:NGNE) added to Russell Small Cap Completeness Index CI

Evolution of the average Target Price on Neurogene Inc.

Price target over the last 5 years

History of analyst recommendation changes

7847024ca.aOJJeaqyvpriepyuVs6RSn-M68U_Z9NiGrFy-nMIrEc.B5cuF53o-LejV-ziH4T8Kx32hqhoIp8lftVLnERkwHBcjTkqxN-Pt5ZLpA~e3248ae36ca43679034f22594eb9c3a1

Analyst Recommendations on Neurogene Inc.

BMO Initiates Neurogene at Outperform With $65 Price Target MT
Baird Initiates Neurogene With Outperform Rating, $54 Price Target MT
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
William Blair Initiates Neurogene With Outperform Rating MT
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target MT
Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating MT
Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy MT
Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21 MT
Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10 MT
BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3 MT
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating MT
Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating MT
Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target MT
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating MT
Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating MT
Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating MT
NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target MT
NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
38.56 USD
Average target price
53.33 USD
Spread / Average Target
+38.31%
High Price Target
65 USD
Spread / Highest target
+68.57%
Low Price Target
44 USD
Spread / Lowest Target
+14.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neurogene Inc.

Baird
Leerink Partners
William Blair & Co.
HC Wainwright
Stifel Nicolaus
Mizuho Securities
Guggenheim
Canaccord Genuity
BofA Securities
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. Consensus Neurogene Inc.